Rachel Lane

Rachel Lane PhD is an experienced executive in the biotechnology and therapeutics sectors, currently serving as the Chief Business Officer at Belharra Therapeutics since August 2021. Rachel has held multiple interim leadership positions including Interim Chief Business Officer at Nighthawk Therapeutics and has contributed to various organizations as a board member and observer, such as at Levator Therapeutics, Kate Therapeutics, and Santa Ana Bio, Inc. Prior roles include Principal at Versant Ventures and Director of Business Development at Calico Life Sciences. Rachel earned a Ph.D. in Molecular and Cell Biology from The University of Sheffield and a BSc (Hons) in Biomedical Sciences from Sheffield Hallam University.